Compare Cincinnati Financial Corporation (CINF) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Ginkgo Bioworks Holdings Inc — how do they compare? Cincinnati Financial Corporation trades at $173.45 (market cap $26.58B), while Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M). The key difference: Cincinnati Financial Corporation is far larger — about 52.6× Ginkgo Bioworks Holdings Inc's market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| CINF | DNA | |
|---|---|---|
Market Cap | $26.58B | $505.73M |
Sector | Financials | Health |
52-Week High | $192.03 | $16.14 |
52-Week Low | $149.79 | $5.48 |
Enterprise Value | $25.71B | $607.68M |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $172.55, down 0.75% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing revenue growth. Strong fundamentals include a low P/E of 8.18, robust ROE of 21.48%, and consistent dividend payments, with a recent H1-26 dividend of $0.94 declared.
Outlook remains cautiously optimistic with a consensus price target of $195, implying potential upside. Key risks include catastrophe losses impacting underwriting results and competitive pressures in commercial lines. The stock offers value based on earnings and dividend history but faces near-term headwinds from recent earnings miss and bearish technicals.
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
